InnoCare Pharma (STU:33C) Retained Earnings: €-588.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:33C InnoCare Pharma Ltd STU:33C
78 GF Score
Price €1.51
GF Value €2.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Retained Earnings?

InnoCare Pharma STU:33C -3.21% 78 Retained Earnings is €-588.4 Mil as of Dec. 2025. GuruFocus rates STU:33C with a GF Score™ of 78/100 and a GF Value™ of €2.29 (Possible Value Trap). The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. InnoCare Pharma's retained earnings for the quarter that ended in Dec. 2025 was €-588.4 Mil.

InnoCare Pharma's quarterly retained earnings increased from Dec. 2024 (€-720.7 Mil) to Jun. 2025 (€-667.1 Mil) and increased from Jun. 2025 (€-667.1 Mil) to Dec. 2025 (€-588.4 Mil).

InnoCare Pharma's annual retained earnings declined from Dec. 2023 (€-649.1 Mil) to Dec. 2024 (€-720.7 Mil) but then increased from Dec. 2024 (€-720.7 Mil) to Dec. 2025 (€-588.4 Mil).


InnoCare Pharma  (STU:33C) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


InnoCare Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for InnoCare Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Retained Earnings Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -491.37 -598.89 -649.10 -720.75 -588.36

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -649.10 -680.74 -720.75 -667.11 -588.36
STU:33C
78GF Score
InnoCare Pharma Ltd STU:33C
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCare Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-588.4 Mil mean?
InnoCare Pharma (STU:33C) has a Retained Earnings of €-588.4 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on InnoCare Pharma and its competitors.
Is InnoCare Pharma's Retained Earnings too high?
InnoCare Pharma's current Retained Earnings is €-588.4 Mil. Overall, InnoCare Pharma has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Retained Earnings compare to VRTX and REGN?
InnoCare Pharma's Retained Earnings of €-588.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current Retained Earnings is €-588.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (STU:33C) is currently considered Possible Value Trap. The stock's GF Value™ is €2.29, compared to a current price of €1.51 — trading 34.1% below its estimated fair value. The current Retained Earnings is €-588.4 Mil. InnoCare Pharma's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For InnoCare Pharma (STU:33C), the current Retained Earnings is €-588.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (STU:33C) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of €1.51 is trading 34.1% below its estimated GF Value™ of €2.29. GuruFocus considers InnoCare Pharma to be Possible Value Trap.

Key valuation signals for STU:33C:

  • Retained Earnings: €-588.4 Mil
  • GF Value™: €2.29 vs. price of €1.51 (34.1% below fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the STU:33C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCare Pharma Business Description

Other Exchanges 09969:Hong Kong688428:China
Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
78GF Score

Get the complete analysis for STU:33C

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€2.29
GF Value